Journal of Drug Targeting

The Journal of Drug Targeting is a subscription-based, peer-reviewed journal published by Taylor & Francis, established in 1993, with a 2025 impact factor of 4.7（Journal of Drug Targeting）是由（Taylor & Francis）出版的订阅制同行评审期刊，1993 年创刊，2025 年影响因子为 4.7。

Scope

• It publishes research on all aspects of drug delivery and targeting for molecular and macromolecular drugs该刊发表关于分子药物与大分子药物递送及靶向各方面研究。
• Coverage includes the design and characterization of carrier systems, whether colloidal, protein or polymeric, for in vitro and in vivo applications收稿范围包括用于体外与体内应用的载体系统设计与表征，涵盖胶体、蛋白与聚合物载体。
• It addresses therapeutic peptides and proteins, nucleic acids such as mRNA, microRNA and siRNA, gene-editing and gene-silencing agents, small molecules, aptamers and monoclonal antibodies涵盖治疗性多肽与蛋白、核酸（如 mRNA、microRNA 与 siRNA）、基因编辑与基因沉默试剂、小分子、适配体与单克隆抗体。
• Diagnostic and imaging applications of targeting technologies, as well as self-regulating and stimulus-responsive delivery systems, are within scope靶向技术的诊断与成像应用，以及自调节与刺激响应型递送系统均在收稿范围。
• It also covers physiological barriers to delivery and ways of overcoming them, such as penetration enhancers and avoidance of the reticulo-endothelial system亦涵盖递送的生理屏障及克服方法，如促渗剂与规避网状内皮系统。

History

• The journal was established in 1993该刊于 1993 年创办。
• It was founded by Alexander Florence of the University of London and Vincent Lee of the Chinese University of Hong Kong由（University of London）的 Alexander Florence 与（Chinese University of Hong Kong）的 Vincent Lee 共同创办。
• Ruth Duncan of Cardiff University served as a former editor（Cardiff University）的 Ruth Duncan 曾任该刊主编。
• It is published by Taylor & Francis, appears ten times a year, and offers a hybrid open access option该刊由（Taylor & Francis）出版，每年出版十期，并提供混合型开放获取选项。

Editors

• The editor-in-chief is Saghir Akhtar, Professor of Pharmacology at the College of Medicine, Qatar University现任主编为（Qatar University）医学院药理学教授 Saghir Akhtar。
• The associate editor is Fakhrul Ahsan of Morgan State University副编辑为（Morgan State University）的 Fakhrul Ahsan。
• Manuscripts receive single-anonymous peer review, and the journal accepts original articles, reviews, commentaries, letters and method articles稿件接受单盲同行评审，刊物接受原创论文、综述、评论、来信与方法类文章。
• Its international editorial board covers drug delivery and nanomedicine, and the journal is indexed in Medline, EMBASE, BIOSIS and Scopus其国际编委会覆盖药物递送与纳米医学领域，该刊被（Medline）、（EMBASE）、（BIOSIS）与（Scopus）等收录。